Aptinyx logo MetLife Investment Advisors LLC reduced its position in Aptinyx Inc (NASDAQ:APTX) by 36.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 9,990 shares of the company’s stock after selling 5,652 shares during the quarter. MetLife Investment Advisors LLC’s holdings in Aptinyx were worth $165,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Legal & General Group Plc purchased a new position in shares of Aptinyx in the 3rd quarter worth $58,000. Great West Life Assurance Co. Can purchased a new position in shares of Aptinyx in the 4th quarter worth $40,000. Wells Fargo & Company MN purchased a new position in shares of Aptinyx in the 3rd quarter worth $185,000. Barclays PLC raised its position in shares of Aptinyx by 87.1% in the 4th quarter. Barclays PLC now owns 9,323 shares of the company’s stock worth $154,000 after buying an additional 4,340 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in shares of Aptinyx in the 4th quarter worth $200,000. 62.98% of the stock is currently owned by institutional investors and hedge funds.
In related news, Director Robert J. Hombach acquired 25,000 shares of the business’s stock in a transaction on Friday, January 25th. The shares were bought at an average cost of $5.53 per share, with a total value of $138,250.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website . Company insiders own 8.47% of the company’s stock.
Several research analysts have commented on APTX shares. Cantor Fitzgerald reissued a “buy” rating and issued a $40.00 price objective on shares of Aptinyx in a research report on Wednesday, January 16th. JPMorgan Chase & Co. lowered Aptinyx from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $30.00 to $8.00 in a research report on Thursday, January 17th. Leerink Swann cut their price objective on Aptinyx from $35.00 to $22.00 and set an “outperform” rating on the stock in a research report on Thursday, January 17th. BMO Capital Markets cut their price objective on Aptinyx to $18.00 and set an “outperform” rating on the stock in a research report on Friday, January 18th. Finally, Zacks Investment Research raised Aptinyx from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a research report on Monday, January 21st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Aptinyx presently has a consensus rating of “Buy” and a consensus price target of $12.95.
NASDAQ:APTX opened at $3.81 on Wednesday. Aptinyx Inc has a 12 month low of $3.44 and a 12 month high of $32.25. The stock has a market capitalization of $124.51 million and a price-to-earnings ratio of -1.44.
Aptinyx (NASDAQ:APTX) last released its quarterly earnings data on Thursday, March 21st. The company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.12. The company had revenue of $1.04 million during the quarter, compared to analysts’ expectations of $1.10 million. As a group, equities research analysts anticipate that Aptinyx Inc will post -2.11 EPS for the current fiscal year.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Further Reading: Growth and Income Funds
Want to see what other hedge funds are holding APTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aptinyx Inc (NASDAQ:APTX). Institutional Ownership by Quarter for Aptinyx (NASDAQ:APTX) Receive News & Ratings for Aptinyx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aptinyx and related companies with MarketBeat.com’s FREE daily email newsletter .
Click here to view original web page at MetLife Investment Advisors LLC Cuts Position in Aptinyx Inc (APTX)